Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer attacks French HTA body's downgrading of Pradaxa

This article was originally published in Scrip

Executive Summary

Following a review of the novel oral anticoagulants (NOACs) in the prevention of stroke and systemic embolism, France's health technology assessment body (HAS) has downgraded the "medical benefit" rating (SMR) of Boehringer Ingelheim's Pradaxa (dabigatran etexilate) from "important" to "moderate".

You may also be interested in...



Subgroups & Missing Data: The Problems Facing HTAs In Europe

The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.

Fair Prices Call Prompts EU Industry To Insist On Innovation Incentives

Participants at a workshop on the EU’s proposed Pharmaceutical Strategy discussed affordability and drug shortages and called for more urgency on the draft HTA regulation.

Rerouting Medical Supplies ‘A Priority’ When Brexit Transition Ends

Medical device and pharmaceutical companies in the UK have again been asked to ensure they have contingency measures in place to deal with potential supply problems at channel ports – this time in preparation for the UK’s formal departure from EU’s single market and customs union at the beginning of 2021.

Topics

Related Companies

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel